Glycosylation is a crucial posttranslational modification that is involved in numerous biological events. Therefore, abnormal glycosylation can impair the functions of glycoproteins or glycolipids and is occasionally associated with cell dysfunction and human diseases. For example, aberrant glycosylation of dystroglycan (DG), a cellular receptor for matrix and synaptic proteins, is associated with muscular dystrophy and lissencephaly. DG sugar chains are required for high-affinity binding to ligand proteins, and thus disruption of DGligand linkages underlies disease conditions. Although their biological significance is well recognized, the sugar-chain structure of DG and its modification enzymes have long remained incompletely elucidated. However, recent seminal studies have finally revealed a highly regulated mechanism for DG glycosylation and have discovered a posttranslational unit, ribitolphosphate, that was not previously known to be used in mammals. This review article introduces the structure, modification enzymes and functions of the sugar chains of DG, and then discusses their relationship to human diseases and therapeutic strategies.
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Dystroglycan (DG) was originally identified in skeletal muscle as a component of the dystrophin-glycoprotein complex (DGC), a membrane-associated molecular complex comprising dystrophin, a large intracellular protein that interacts with the actin cytoskeleton, and several dystrophin-associated proteins and glycoproteins (Fig. 1) . Mutations in the dystrophin gene are associated with Duchenne muscular dystrophy, the most frequent form of muscular dystrophy, and mutations in several DGC components also cause various forms of muscular dystrophy. Muscular dystrophy is a group of genetic diseases characterized by progressive weakness of the skeletal muscle, and thus the DGC is considered to provide physical stability to the muscle plasma membrane. DG is composed of a and b subunits that are encoded by a single mRNA and then posttranslationally cleaved into the two subunits (1) . a-DG, a heavily glycosylated extracellular protein that serves as a receptor for matrix and synaptic proteins, is anchored on the plasma membrane through noncovalent interaction with b-DG, a transmembrane protein that interacts intracellularly with dystrophin. Thus, DG plays a central role within the DGC by physically linking the cytoskeleton and the basement membrane across the plasma membrane (2) . In 2001, Hayashi et al. reported abnormal glycosylation of a-DG in patients with Fukuyama congenital muscular dystrophy (FCMD) (3) . Subsequently, Campbell's group provided direct evidence for abnormal glycosylation and reduced ligand-binding activity of a-DG in WalkerWarburg syndrome (WWS) and muscle-eyebrain disease (MEB) in addition to FCMD (4). These diseases are congenital muscular dystrophies accompanied by central nervous system and eye abnormalities. After these reports, several forms of muscular dystrophy involving abnormal glycosylation and their causative genes were successively identified. Currently (in 2017), 18 causative genes for muscular dystrophy with abnormal glycosylation are recognized. Because aberrant a-DG glycosylation is a common biochemical feature of all these disorders regardless of the gene that is mutated, the diseases are collectively called dystroglycanopathies (DGpathies) (5, 6) . Details regarding dystrophin and its associated proteins and the clinical features of DGpathies are reviewed elsewhere (79) .
DG Sugar-Chain Structure and Enzymes for its Modification

CoreM1 and CoreM3
In the early 1990s, O-glycosylation was shown to be critical for DG ligand-binding activity. Endo and colleagues then initiated structural studies and identified, from purified bovine a-DG, a unique O-mannose (Man)-type glycan, Siaa23Galb14GlcNAcb12Man (11), a structure later named CoreM1 (12) . The GlcNAcb12Man linkage is catalyzed by protein O-mannose beta-1, 2-Nacetylglucosaminyltransferase (POMGnT1), which transfers GlcNAc from UDP-GlcNAc to O-mannosyl proteins (13) . POMGnT1 was cloned by searching for cDNA sequences homologous to that of UDP-N-acetylglucosamine: a-3-D-mannoside b-1, 2-N-acetylglucosaminyltransferase I (GnT-I), an enzyme that catalyzes the GlcNAcb12Man linkage in N-glycans. Human POMGNT1 is located at 1p33-34, and, intriguingly, the MEB gene locus was also mapped to 1p32-34. By collaborating with Toda's group, they identified POMGNT1 mutations in MEB patients (13) . This was the first finding suggesting a link between glycosylation and muscular dystrophy. CoreM1 can be further modified with a b1, 6-GlcNAc branch through the enzymatic action of N-acetylglucosaminyltransferase-IX [GnT-IX; also called mannosyl (alpha-1, 6-)-glycoprotein beta-1, 6-N-acetylglucosaminyltransferase, isozyme B (MGAT5B)] (14, 15) . This branch structure is named CoreM2 (12) . CoreM2 appears in a very minor population of skeletal muscle a-DG, and GnT-IX absence does not affect DG function in the brain (1517). However, because CoreM2 accounts for a fraction of brain O-glycans (16), it might play biological roles through glycoproteins other than DG (15, 17) .
O-mannosylation has been well studied in yeast because O-mannosylated proteins are abundant in the yeast cell wall. In yeast, the initial formation of the mannosyl-peptide linkage is catalyzed by protein Omannosyltransferases (PMT). In 2002, mutations in protein O-mannosyltransferase 1 (POMT1), a human PMT homolog, were identified in WWS patients (18) . Subsequently, Manya et al. demonstrated that POMT1 forms a heterocomplex with POMT2, another human PMT homolog, and this POMT1/POMT2 complex formation is required for O-mannosyltransferase activity (19) . Later work identified POMT2 mutations in WWS and limb-girdle muscular dystrophy patients (20) . The POMT1/POMT2 complex localizes in the endoplasmic reticulum (ER) and catalyzes Man transfer from dolicholphosphate mannose (Dol-P-Man) to Ser/Thr residues.
In the mid-2000 s, six DGpathy genes were known, POMT1, POMT2, POMGNT1, fukutin, fukutin-related protein (FKRP), and like-acetylglucosaminyltransferase (LARGE) (13, 18, 2024) , but mutations in these genes did not account for all DGpathy cases. This suggested the existence of other genes responsible for DG glycosylation and perhaps unidentified sugar-chain structures on DG. In 2010, Campbell's group identified a previously unrecognized O-Man-type glycan, GalNAcb13GlcNAcb14Man, on recombinant a-DG expressed in HEK cells (25) . This structure was named CoreM3 (12) , and, interestingly, CoreM3 was phosphorylated at the C6 position of Man (26) (26) , which is synthesized in the ER. The initial Man transfer is catalyzed by the POMT1/POMT2 complex, as in CoreM1 synthesis, and the GlcNAcb14Man linkage is catalyzed by POMGnT2, which transfers GlcNAc from a UDP-GlcNAc to the O-mannosyl peptide of DG. The GalNAcb13GlcNAc linkage is synthesized by B3GALNT2, which transfers GalNAc from a UDP-GalNAc. O-Man phosphorylation, which is catalyzed by POMK, is required for subsequent ribitol (Rbo)-phosphate (RboP) modification on CoreM3. POMK was regarded as a pseudokinase because it lacks functional motifs present in typical kinases, but recent crystal-structure studies have revealed the POMK catalysis and substrate-recognition mechanisms (34, 35) .
Dol-P-Man
Because the POMT1/POMT2 complex uses Dol-PMan for the initial Man transfer, defects in the Dol-P-Man biosynthesis pathway could potentially disrupt DG O-mannosylation. Dol-P-Man also acts as a Man donor for N-glycosylation and glycophosphatidylinositol-anchor biosynthesis. Here, we introduce several genes in this pathway whose mutations cause DGpathies. The details of Dol-P-Man biosynthesis have been described in an excellent review (36) .
The dolichol-phosphate mannosyltransferase (DPM) complex, comprising the catalytic DPM1 and the transmembrane DPM2 and DPM3, synthesizes Dol-P-Man from GDP-Man and dolicholphosphate. Mutations in DPM1, DPM2, or DPM3 have been identified in DGpathy patients who also show a type I congenital disorder of glycosylation (CDG) (3739). CDG is a heterogeneous group of genetic disorders that were originally defined to involve N-glycosylation defects but now also include O-linked-and lipid-glycosylation defects. Besides the DPM-complex genes, a few other DGpathy causative genes are recognized: Mutations in the gene encoding dolichol kinase (DOLK), which catalyzes dolicholphosphate formation, were identified in CDG patients with dilated cardiomyopathy, whose heart tissue shows abnormal DG O-mannosylation (40) . Mutations in the gene encoding GDP-mannose pyrophosphorylase B (GMPPB), which functions in GDP-Man formation from Man-1-phosphate and GTP, were also reported in DGpathy patients (41) . Although defects in Dol-P-Man synthesis could affect both O-mannosylation and N-glycosylation on proteins other than DG, the original report on GMPPB mutations presented no evidence for perturbation of N-glycosylation. Further investigation is required to clarify the mechanism by which mutations in the Dol-P-Man synthesis pathway selectively or preferentially affect Omannosylation or N-glycosylation.
Matriglycan
The antibody IIH6 recognizes functionally glycosylated a-DG and competes with DG ligand binding; thus, IIH6 was considered to recognize laminin-binding epitopes on sugar chains. A 2004 report showed that LARGE overexpression drastically enhances IIH6 reactivity and laminin-binding activity of a-DG (10), which suggested that LARGE participates in the synthesis of the ligand-binding moieties. LARGE is the gene mutated in congenital muscular dystrophy 1 D (MDC1D) (24) and spontaneous-mutant Large myd mice (42) . In 2012, Inamori et al. reported that LARGE exhibits both xylosyltransferase and glucuronyltransferase activities and produces repeating units of [3GlcAb13Xyla1] (GlcA-Xyl) by using UDP-GlcA and UDP-Xyl as donor substrates (43) . The enzymatically synthesized GlcA-Xyl repeat was shown to bind both IIH6 and laminin. Subsequently, the GlcA-Xyl repeat was detected in recombinant a-DG even without LARGE overexpression (44) . These findings established that the GlcA-Xyl repeat serves as a binding motif for matrix proteins, and thus the name 'matriglycan' was proposed for this polysaccharide structure (12) .
For LARGE-dependent a-DG modification, besides LARGE enzyme activities, physical interaction between LARGE and the a-DG N-terminal domain is necessary, although the matriglycan modification occurs on Ser/Thr residues in the mucin-like domain (10, 45) . This interaction might recruit LARGE to DG and provide enzyme-substrate specificity to ensure this unique and biologically highly specific modification. The a-DG N-terminal domain is cleaved by furin-like proteases, likely during translocation to the plasma membrane (10) . The biological relevance of this cleavage is unknown, but given that LARGE-dependent glycosylation occurs a few amino acids downstream from the cleavage site, the cleavage might generate a stereochemically beneficial conformation for ligand interaction. In 2011, a mutation in the DG gene, DAG1, was identified in DGpathy patients (46) ; the mutation locates in the N-terminal domain and reduces DG binding to LARGE, which results in aberrant a-DG glycosylation.
LARGE2 (also called glycosyltransferase-like 1B, GYLTL1B), a LARGE1 paralog, also exhibits both xylosyltransferase and glucuronyltransferase activities and synthesizes GlcA-Xyl repeats on a-DG (47, 48) . Although LARGE1 is likely specific to DG, LARGE2 can also modify proteoglycans such as glypican-4 (49). Intriguingly, LARGE2-dependent proteoglycan modification appears to be independent of O-mannosylation. How LARGE1 and LARGE2 appropriately function in DG modification is unclear, but this might depend on their tissue distribution because LARGE1 and LARGE2 show distinct tissue-expression profiles: whereas LARGE1 is highly expressed in the brain, heart and skeletal muscle, LARGE2 is abundant in kidney and testis. LARGE2 mutations have not been identified in human DGpathy patients as of 2017.
The enzyme activity of human natural killer-1 sulfotransferase (HNK1-ST) has been reported to suppress a-DG glycosylation and ligand-binding activity, possibly through sulphate-group incorporation (50, 51): HNK1-ST transfers a sulphate group to the C3 position of GlcA in matriglycan, which could inhibit LARGE-dependent elongation of matriglycan. Thus, sulfation might represent a regulating factor for matriglycan length and activity.
Tandem RboP
Identification of the enzyme systems for the synthesis of CoreM3 and the LARGE-dependent ligand-binding moiety in the early 2010s was a breakthrough, but several DGpathy gene functions remained unrevealed; this raised the possibility that an unidentified moiety present between CoreM3 and ligand-binding GlcA-Xyl repeats might be synthesized by DGpathy gene products whose functions were unknown. However, complete elucidation of the a-DG glycan structure was precluded by experimental challenges: (i) established methods for analysing glycan structure were unavailable; (ii) sufficient amounts of glycoproteins could not be readily obtained from native tissues or cells; and (iii) most of the recombinant DG expressed in cultured cells was not functionally glycosylated with GlcA-Xyl repeats. We initiated glycan structural analysis by searching cell lines that effectively modify recombinant DG with GlcA-Xyl repeats (44) . Among several cell lines, only NIH3T3 cells showed high-efficiency functional glycosylation of recombinant DG even without LARGE coexpression. The next hurdle was that the a-DG mucin domain contains >40 potential O-Man sites; this generates very heterogeneously glycosylated recombinant proteins. Moreover, the high molecular weight resulting from repeating GlcA-Xyl residues made glycopeptide analysis through mass spectrometry (MS) challenging. Because the first two Thr residues in the mucin-like domain were reported as putative functional-glycosylation sites (45), we generated a deletion construct containing only the first 20 amino acids in the mucin domain to overcome these obstacles. MS analysis of purified recombinant DG revealed the presence of repeating units consisting of a GlcA and a Xyl. These data provided the first direct evidence for matriglycan modification on a-DG. We also analysed a recombinant DG from which the putative linker structure was removed through chemical treatment, and another recombinant DG harbouring a point mutation that inhibits LARGE-dependent GlcA-Xyl modification (46) . Comparison of the MS data on these glycopeptides and the more detailed MS and composition-analysis data obtained subsequently revealed that the linker structure contains one GlcAXyl unit and a tandemly connected RboP.
Rbo is a sugar alcohol, and RboP is used as a component of the teichoic acids present in the cell wall of gram-positive bacteria (52) . Rbo and RboP use in mammals was unrecognized, and therefore their biosynthesis pathway was completely unknown. In bacteria, the RboP polymers in teichoic acids are synthesized by enzymes that use, as a donor substrate, CDP-Rbo, which is synthesized from CTP and RboP by the enzyme teichoic acid ribitol I (TarI). We found that bacterial TarI shares homology with human ISPD, whose mutations were identified in 2012 to cause DGpathy (27, 28) . In 2015, crystal-structure analysis revealed that the human ISPD cytidyltransferase domain superimposes well with a series of closely related prokaryotic cytidyltransferases and bacterial TarI (53) . Next, we confirmed that human ISPD possesses CDP-Rbo synthase activity, which was reduced by missense mutations identified in patients (44) . Shortly thereafter, two other groups independently confirmed that human ISPD catalyzes CDP-Rbo synthesis as a CDP-Rbo pyrophosphorylase (54, 55) .
At this juncture, the DGpathy genes with unknown function were fukutin, FKRP and TMEM5. Because RboP appears in tandem form, we suspected that fukutin and FKRP, which share homology, participate in the synthesis of this unique structure. Accordingly, we demonstrated that fukutin transfers RboP from a CDP-Rbo to GalNAc in CoreM3, and then FKRP transfers RboP from a CDP-Rbo to the first RboP (44) . Thus, the tandem-RboP structure is synthesized through the sequential actions of fukutin and FKRP as RboP transferases. The linker structure also contains a GlcAb1-4Xyl unit that is connected to the tandem RboP and serves as a primer for the initiation of LARGE-dependent matriglycan formation. This unit is formed by TMEM5 and B4GAT1: TMEM5 acts as a ribitol b1, 4-xylosyltransferase to generate a Xylb1-4Rbo5P linkage, in which the second RboP in the tandem structure serves as the acceptor for Xyl (56) ; this function is the basis for the proposal that TMEM5 could be renamed RXYLT1 (Rbo5P b1, 4-Xyl transferase) (57, 58) . B4GAT1, originally known as b-1, 3-N-acetylglucosaminyltransferase 1 (B3GNT1) or I-beta-1, 3-N-acetylglucosaminyltransferase (iGnT), shares homology with the glucuronyltransferase domain of LARGE and catalyzes the formation of the GlcAb1-4Xyl linkage by transferring GlcA from UDP-GlcA to Xyl (59, 60) .
In a recent review, the name ribitol b-1, 2 xylosyltransferase was proposed for TMEM5 (57) . This difference from the original naming by Manya et al. in which the C5 position of Rbo is modified with phosphate. According to this nomenclature, the tandem-RboP structure with a Xyl modification is Xylb1, 4-Rbo5P-1Rbo5P. However, CDP-L-ribitol has also been named based on R/S nomenclature for CDP-Rbo; using this nomenclature, the structure can be alternatively referred to as Xylb1, 2-Rbo1P-5Rbo1P and TMEM5 can be referred as ribitol b-1, 2 xylosyltransferase. We have indicated here this naming inconsistency resulting from the mixed use of R/S and D/L nomenclatures, and have used in this review the names reported in the original research articles.
The fact that so many enzymes are involved in the glycosylation of a single protein, DG, in order to activate its laminin binding activity (see next section), and that a mutation in just one gene in this biosynthetic pathway leads to muscular dystrophy, suggests that DG requires a highly organized series of modifications (CoreM3, tandem Rbo and matriglycan) and high binding affinity to laminin. Although the reason for this is unknown, this unique modification may be important for the physical maintenance of movable tissues such as skeletal and cardiac muscles. Although it is possible that there are proteins other than DG modified by ribitol, as of 2018, ribitol has only been found in DG. The unique ribitol-containing moiety may play an important role in the determination of substrate specificity for matriglycan modifications and may also provide preferential structural conformations when matriglycan binds to laminin and other ligand proteins.
Relationship between CoreM1 and CoreM3
CoreM1 defects caused by POMGnT1 mutation result in the loss of DG ligand-binding activity. However, the ligand-binding matriglycan is modified on CoreM3. How do CoreM1 defects affect DG functional maturation? After the initial Man transfer to DG core peptides by the POMT1/POMT2 complex in the ER, CoreM1 is synthesized by Golgi-resident POMGnT1, whereas CoreM3 is synthesized and phosphorylated in the ER. Thus, CoreM1 is considered to affect modifications occurring in the Golgi (tandem-RboP or matriglycan modifications). Kuwabara et al. recently reported that the POMGnT1 stem domain binds to carbohydrates including the disaccharide GalNAcb1-3GlcNAcb-, which is a part of CoreM3 structure (61) . POMGnT1 was also reported to physically interact with fukutin in the Golgi through their transmembrane domains (62) . These reports suggest that POMGnT1 recognizes CoreM3 and recruits fukutin close to CoreM3 and thus facilitates RboP transfer. How CoreM3 synthesis is also affected by missense mutations in the POMGnT1 catalytic domain that diminish enzyme activity is unclear, but the mutations might affect protein structure and/or stability. Intriguingly, crystal-structure analysis revealed that POMGnT1 also binds to its product GlcNAcb1-2Mana-peptide. This interaction might increase the overall POMGnT1 affinity for DG and facilitate subsequent GlcNAc modifications on other nearby O-Man residues. Accordingly, glycomics analysis revealed that numerous O-mannosylated sites in DG are extended with b1, 2-GlcNAc, forming CoreM1 clusters (16) . However, the role of CoreM1 clusters in DG is unknown and further investigation in necessary to clarify the role.
a-DG Ligands
To function as a receptor for extracellular matrix or synaptic proteins, a-DG requires proper modification with matriglycan. Therefore, a-DG-ligand interactions are drastically disrupted in DGpathies. The currently known ligand proteins include laminins (1, 63, 64) , agrin (65, 66) , perlecan (67), neurexin (68) , pikachurin (69) and Slit (70); all these DG ligands contain laminin G-like (LG) domains, which serve as a-DG-binding sites. Here, we briefly introduce the DG ligands and their binding mechanism (Fig. 3) .
Laminins, which are major basement-membrane components, are heterotrimeric proteins composed of one each a, b and g chains; laminin a-chain contains LG domains. In the skeletal muscle basement membrane, the principal laminin is laminin-211 (a2b1g1; named according to chain composition), whose interaction with DG is essential for maintaining skeletal muscle function. Conversely, agrin-DG interaction plays crucial roles in neuromuscular junction maintenance. Perlecan is a major component of the basement membrane; the precise function of perlecan-DG interaction is unknown, but its high binding affinity indicates specific roles for the interaction (63) . Neurexins are transmembrane proteins expressed in the nervous system; the physiological role of neurexin-DG interaction is unknown, but the interaction might be involved in synapse formation and/or maintenance, considering that neurexins are localized on the Dystroglycan glycosylation and muscular dystrophy presynaptic membrane and DG is on the postsynaptic membrane. Pikachurin is expressed in the synaptic cleft of photoreceptor ribbon synapses, and pikachurin-DG interactions play roles in the maintenance of retinal synapse structures, synaptic signal transmission and visual functions (69, 71) . Slit functions as a repulsive axon-guidance cue, and DG is required for proper Slit localization, which potentially suggests a previously unrecognized function of DG as an extracellular scaffold for controlling axon guidance.
DG-ligand interactions require Ca 2+ , and the LG domains in the ligand proteins commonly contain Ca 2+ -coordinating residues. Laminin a2-chain LG4-5 domains (tandemly connected fourth and fifth LG domains) serve as DG-binding sites, and crystal-structure analysis revealed that a single GlcA-Xyl disaccharide coordinates Ca 2+ in the LG4 domain (72) . NMR analysis confirmed that the single GlcA-Xyl disaccharide can interact with LG4-5; however, higher binding affinities were measured with increasing lengths of GlcAXyl repeats, which indicated the statistical effect of multiple binding sites in GlcA-Xyl repeats. Thus, multiple GlcA-Xyl repeats might be necessary for increasing the apparent affinity to LG domains by favouring rapid rebinding after dissociation. Similarly, several ligand proteins require tandemly connected LG domains for DG binding, which indicates that multiple Ca 2+ binding sites are necessary for high-affinity binding. The DG-ligand interaction was considered to be mediated by electrostatic interactions, but this could not explain the tight binding. As introduced in this paragraph, the recent structural analysis has clearly demonstrated the mechanism underlying the high affinity noted for glycosylation-dependent DG-ligand binding.
Can several ligand proteins concurrently bind to a single long chain of GlcA-Xyl repeats? GlcA-Xyl repeats are expected to extend into the hundreds, and thus >1 ligand molecule could bind to a single GlcAXyl chain (72) . Conversely, in solid-phase or blotoverlay binding assays, ligands bind competitively to DG (73) . This discrepancy remains to be resolved experimentally, but under physiological conditions, various ligand proteins should be in excess relative to a single DG protein. According to the widely accepted receptor-facilitated matrix-assembly model, both initial laminin binding to DG and subsequent laminin self-association facilitate the assembly of other matrix proteins, including DG's ligand perlecan, for the matrix-network formation on the cell surface (74) .
Dystroglycan is also a cellular receptor for Old World arenaviruses, including Lassa fever virus and lymphocytic choriomeningitis virus (75) . This virus binding also requires matriglycan modification, and the binding sites partly overlap with those of matrix ligands, but the virus binding does not require Ca 2+ (76) . Recent work is establishing a previously unrecognized aspect of the complex virus-host interaction, including the molecular mechanism of receptor recognition and endocytosis, and the use of late-endosomal entry factors (77) .
Physiological Roles of RboP Modification
Because RboP is an indispensable moiety for matriglycan formation, its physiological and pathological functions overlap with those of matriglycan. Here, we introduce the physiological functions of RboP modification that were revealed from studies using fukutindeficient mice and spontaneous Large-deficient Large myd (myd) mice. Homozygous fukutin-null mice were embryonic lethal, and the developing embryos exhibited basement-membrane defects, which indicated a pivotal role of RboP modification in basement-membrane function (78) . To elucidate the physiological roles of RboP modification in adult tissues, we generated skeletal muscle-selective fukutin conditional knockout (cKO) mice. Myotube-selective fukutin-deficient mice generated using muscle creatine kinase (MCK)-Cre mice (MCK-fukutin-cKO mice) showed plasma membrane weakness, which preceded disease onset (79) . Moreover, in certain myofibers obtained from myd mice, the basement membrane was detached from the muscle plasma membrane (80) . These structural abnormalities likely render muscles prone to contraction-induced injuries, eventually leading to muscle-cell necrosis. Thus, RboP moieties and matriglycan maintain the plasma membrane and basement-membrane structure and thereby provide physical strength to muscle cells. Following myofiber injury, satellite cells, which are skeletal muscle-specific stem cells, become activated and differentiate into muscle precursor cells (MPCs), which fuse into myotubes. This process enables skeletal muscle regeneration. MPC-selective fukutin-deficient mice generated using myogenic factor 5 (Myf5)-Cre mice (Myf5-fukutin-cKO mice) exhibit impaired MPC proliferation and differentiation, and, consequently, delayed muscle regeneration (79) , which indicates physiological roles of RboP and matriglycan modifications in the maintenance of MPC function.
Structural abnormalities in the brain represent a pathological hallmark of DGpathy, which suggests that DG glycosylation also plays critical roles in brain development. FCMD fetal brain autopsy revealed neurons protruding into the subarachnoid space through sites showing basement-membrane breaches (9) . Several DGpathy model mice also exhibit pathological abnormalities such as neuron over-migration, basement-membrane breakdown and cerebralhemisphere fusion (4, 81, 82) . These studies indicate that DG in radial glia functions in maintaining the physical stability of the glia limitans/basement-membrane complex in a glycosylation-dependent manner, and its disruption might underlie the causes of cortical dysplasia and type II lissencephaly. DG was also detected at the postsynaptic apparatus of synapses established by mossy fibers on the cell bodies and dendrites of CA3 and CA1 pyramidal neurons (83) . In hippocampal-neuron cultures, DG colocalizes with a subset of inhibitory synapses (84). Campbell's group showed impaired long-term potentiation at CA3-CA1 synapses in myd and neuron-selective DG-deficient mice (81).
These observations raise the possibility that DG regulates synaptic functions.
Therapeutic Strategies for DGpathy with RboP-modification Defects
Mutations in ISPD, fukutin or FKRP cause DGpathy with defects in RboP modification, and thus these cases can be collectively categorized into a DGpathy subgroup. Here, we introduce several therapeutic strategies for DGpathy with RboP-modification defects, proposed based on the results from pathological analysis performed using disease-model animals or cells.
Because DGpathy is a single-gene disorder, gene replacement is the most straightforward treatment strategy. As an initial step in developing therapeutic strategies, it is crucial to show that introducing normal versions of disease-causing genes into diseasemodel animals improves pathological phenotypes. Several groups, including ours, have shown that gene therapy efficiently ameliorates dystrophic phenotypes and improves muscle function even after disease progression (79, 85) .
We have also proposed therapeutic strategies based on the unique pathogenesis of DGpathy with RboPmodification defects. FCMD is the most prevalent DGpathy and the second most common childhood muscular dystrophy in Japan. Most FCMD patients carry a retrotransposal insertion in the fukutin 3 0 -UTR; this insertion contains a strong splice-acceptor site, which induces a rare alternative donor site in the last exon, and thus causes abnormal mRNA splicing (exon trapping) (86) . Introduction of antisense oligonucleotides targeting the splice-acceptor and splicing-enhancer sequences can prevent the pathogenic exon trapping. Consequently, this treatment restores normal fukutin mRNA expression and protein production and a-DG glycosylation in FCMD patient cells and retrotransposon knock-in model mice. Because the retrotransposal insertion is the founder mutation, this strategy can be applied to almost all FCMD patients in Japan.
In ISPD-deficient DGpathy, reduction or loss of cellular CDP-Rbo impairs RboP modification, affecting subsequent matriglycan formation. Thus, CDP-Rbo supplementation should represent an effective therapeutic strategy. Accordingly, CDP-Rbo addition to the culture media of ISPD-deficient cells rescued RboP and matriglycan modifications (44) . ISPD-dependent CDP-Rbo synthesis requires Rbo5P, although the details of the RboP biosynthetic pathway remain unknown. However, because D-ribose or ribitol addition to ISPD-overexpressing cells increased cellular CDP-Rbo concentrations (55), these are candidate metabolites in the Rbo5P synthesis pathway. Interestingly, ribitol inclusion in drinking water resulted in increased muscle CDP-Rbo levels in wildtype mice (55) , which suggests that supplementation of metabolites in the Rbo5P synthesis pathway might increase cellular Rbo5P levels and thus enhance the CDP-Rbo synthase activity of disease-causing mutant-ISPD proteins. Further studies will be necessary for developing CDP-Rbo or metabolite-supplementation therapy.
Conclusions
Identification of diseases caused by abnormal DG glycosylation has markedly influenced diverse research fields-not just the muscular dystrophy field, but also fields such as glycobiology and neurobiology-and has helped in establishing the biological importance of sugar chains. The past few years have seen the discovery of the complete structure of functional glycans and their modification enzymes. Notably, each milestone study in this long research journey has also brought biochemically and biologically significant breakthroughs. The original finding of the CoreM1 glycan opened a new avenue of research on O-mannosyl glycosylation in mammals, and several O-mannosylated proteins besides DG are now known. Identification of the tandem-RboP structure revealed a previously unrecognized posttranslational modification in humans. We expect a new stream of research to be focused on elucidating the Rbo5P biosynthesis pathway and identifying additional proteins modified with Rbo5P. Studies conducted using genetically engineered mice have revealed the physiological functions of DG glycosylation and the pathomechanism of DGpathies. These studies have also considerably facilitated the establishment of innovative therapeutic strategies for DGpathies. Our hope is that these basic research studies will contribute toward developing treatments that can overcome muscular dystrophy and related diseases.
